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Due to the high cost of treatment, preventative measures to limit Hepatitis C (HCV) transmission among people
who inject drugs (PWID) are encouraged bymany public health officials. A key one of these is serosorting, where
PWID select risk partners based on concordant HCV status. Research on the general U.S. population by Smith et al.
(2013) found that knowledge of one's own HCV status facilitated serosorting behaviors among PWID, such that
respondents with knowledge of their own status were more likely to ask potential partners about their status
prior to sharing risk. Our objective was to see if this held true in rural Puerto Rico. We replicate this study
using a sample of PWID in rural Puerto Rico to draw comparisons.Weused respondent driven sampling to survey
315 participants, and have a final analytic sample of 154. The survey was heavily modeled after the National HIV
Behavioral Survey, which was the dataset used by the previous researchers. We found that among PWID in rural
Puerto Rico, unlike in the general population, knowledge of one's ownHCV status had no significant effect on the
selection of one's most recent injection partner, based on his/her HCV status. We conclude that PWID in rural
Puerto Rico differ from the general U.S. population when it comes to serosorting behaviors, and that these differ-
ences should be taken into account in future outreaches and intervention strategies.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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1. Introduction
Recent research on a national CDC data base of people who inject
drugs (PWID) Smith et al. (2013) found that participants who knew
their own Hepatic C (HCV) status were more likely to ask potential in-
jection partners about their HCV status before sharing injection equip-
ment than participants who didn't know their own HCV status. The
goal of this inquiry is to find partners who are of concordant HCV status
and share onlywith them, so uninfected PWID do not contract Hepatitis
C. This is a process known as “serosorting,” (Smith et al., 2013). While
these national-level findings are significant, we seek to replicate one
of the models in this study using data collected in rural Puerto Rico, in
order to draw comparisons between rural Puerto Rican PWID and the
general U.S. population of PWID in regards to their serosorting
behaviors.
It is well known that the behavior and norms of PWID vary from
community to community, and this is no different with serosorting. A
2007 study comparing PWID in five U.S. cities found that perceived
peer norms condoning needle sharing were the biggest factor associat-
ed with serosorting and needle sharing behaviors (Golub et al., 2007).
Such peer norms have been shown to apply to ethnic sub-populations
within larger PWID communities. Puerto Rican PWID living in the U.S.
are more likely to share needles with one another (Deren et al., 2001)
and twice as likely to take part in indirect equipment sharing (Andía
et al., 2008) as non-Puerto Rican PWID in these same areas. Additional
research found that Puerto Rican PWID who recently immigrated to
New York City reported more risky injection behavior than those who
were not new immigrants (Deren et al., 2003). These differences have
immediate consequences: one study comparing New York PWID who
identified as Puerto Rican to PWID who lived in Puerto Rico found that
the latter had over four times the annual mortality rate of their New
York counterparts (Colon et al., 2006). In part, this is due to radical dis-
parities in availability of care. Here we argue that underlying these dis-
parities are large differences in behavior and disposition to risk.
Hepatitis C is a public health issuewith the potential for serious con-
sequences if left unattended. First discovered in 1989 (Choo et al.,
1989), recent reports suggest that 2.7 million Americans are chronically
HCV+ (Denniston et al., 2014), and worldwide between 130 and 170
million people, or 2 to 3% of the population, is infected with HCV
(Averhoff et al., 2012). Of these, approximately 500,000 die each year
as a result of HCV infection related diseases (Lozano et al., 2012). HCV
is a blood borne virus, putting PWID at a particularly high risk of infec-
tion. Current research suggests that approximately one third of PWID
under age 30 are infected with HCV, and prevalence among older and
former PWID ranges from 70 to 90% (U.S. Centers of Disease Control
and Prevention, 2015a). In recent years, deaths as a result of HCV have
outpaced those from the human immunodeficiency virus (HIV) in the
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U.S. (Ly et al., 2012). Among PWID in particular, incidence and preva-
lence rates of HCV infection (Hahn et al., 2002; Roy et al., 2007) have
far surpassed those of HIV (Mehta et al., 2006).
One reason for this is that the HCV virus is highly robust in compar-
ison to HIV, capable of surviving for days without a host, particularly in
some types of syringes (Paintsil et al., 2010) and injection works like
cookers and cotton (Abadie et al., 2016). Additionally, a March 2014
CDC report states that 80% of PWID with HIV are co-infected with HCV
aswell (U.S. Centers of Disease Control and Prevention, 2015b), indicat-
ing that in many situations, potential HCV infections confront individ-
uals with reduced immune function.
Current common HCV treatment typically involves taking prophy-
lactic medications, which have been found effective in 43 to 80% of pa-
tients, depending on the genotype of the infection (Manns et al., 2001).
When these treatments do work, though, they come with problematic
side effects (Alvarez et al., 2006). Additionally, a new HCV treatment
drug, Sofosbuvir, has recently come on to themarket. Though it has po-
tential to treat HCVmore effectively than currentmethods, it's high cost
must be weighed against these benefits (Berden et al., 2014).
Because HCV is spread in much the same way as HIV, interventions
to curb HCV transmissions are often patterned after HIV interventions.
A common one is the “testing as intervention” method. Here, PWID
are tested for the Hepatitis C virus and/or HIV and encouraged to
serosort when selecting injection partners. However, the majority of
serosorting research has been done on sexual partner selection, not in-
jection partner selection (Cox et al., 2004; Fendrich et al., 2010;
Zablotska et al., 2009). In regards to sexual transmission, there is indeed
reason to believe that serosorting reduces the risk of HIV infection
(Philip et al., 2010), and the practice is recommended for sexual risk
by the CDC (Serosorting|HIV Risk Reduction Tool|CDC, 2016).
Concerning infection through co-injection, one study focusing spe-
cifically on HIV found that approximately 40% of PWID regularly
serosorted (Mizuno et al., 2011). Earlier research on HCV serosorting
among PWID found a similar proportion (Burt et al., 2009). Despite
the similar percentage of serosorting, Hepatitis C is not considered a se-
rious threat in some PWID communities, at least in comparison to HIV.
One recent study found that 86% of Seattle PWID and 90% of those in
Denverwhoknew they had anHCV infection failed to get treatment, de-
spite outreach programs available in the community (Al-Tayyib et al.,
2015). Other research suggests that many PWID see infection as an un-
avoidable consequence of injecting (Rhodes et al., 2004).
2. Methods
Interviews with 315 participants were completed between April
19th, 2015 and June 15, 2015 in rural areas approximately
30–40 miles from San Juan, Puerto Rico, drawing participants from
several surrounding towns. We worked with El Punto en la Montaña,
a syringe exchange program operating in these areas, to facilitation
data collection. All information was collected in private research offices
or a similar, confidential interview space. Eligible participants were
alert, 18 years of age or older, and reported injecting drugs within the
last 30 days. Visual inspections for injection signs, as well as question-
naires about drug injection knowledge, were used to confirm this.
Upon completing the questionnaire, participants were compensated
with $25. Recruitment into the sample was managed using respondent
driven sampling (RDS)whereby participantswho completed the survey
were given three referral coupons they could pass out to other qualified
individualswhohadnot previously participated in the project. For every
referral that then completed the survey, the referee could earn an addi-
tional $10. Thismethod of recruitment is often preferred for stigmatized
populations (Heckathorn, 2002). The study received IRB approval
through the University of Nebraska-Lincoln (IRB# 20131113844FB)
and the University Of Puerto Rico School Of Medicine (IRB#
A8480115). Additional details about the sampling procedure can be
found in previous work using the data (Abadie et al., 2016).
The questionnaire itself was interviewer-administered and based on
the CDC NHBS IDU Round 3 Questionnaire version 13. The instrument
asked questions about injection behavior, prior HCV and HIV status
and testing, and several other topics related to drug use and HIV/HCV
risk. In addition to recording the participants' self-reported HCV and
HIV status prior to participating in the study, the project provided
rapid testing for both HIV and HCV - INSTI Rapid HIV antibody tests
(Biolytical Laboratories) and OraQuick HCV Rapid antibody tests
(OraSure Technologies). Participants were compensated an additional
$5 for each test completed. Participants who tested positive for HCV or
HIV were offered referral and transportation to a primary care doctor
for confirmatory testing and link-to-care.
The current analysis replicates Model 2 from Smith et al., which ex-
amined if participants could have attempted to serosort on their last in-
jection partner, or simply if they had knowledge of their last injection
partner's HCV status (Smith et al., 2013). It does not examine how par-
ticipants used this information: only if they sought it. The exact phrasing
of this question is as follows: “The last time you injected with this person
[last injection partner], did you know if they had been tested for Hepatitis
C?” The factors for asking your potential partner about their HCV status
before co-injecting discussed by Smith et al. include 1) self-reported
HCV status, 2) gender, 3) birth year (age), 4) education (high school
graduate vs. not), 5) ever homeless, 6) employment status, 7) income,
and 8) age at first injection. Multivariate logistic regressions were per-
formed and adjusted odds ratios, where all variables are placed in the
model at once to control for one another, were calculated to assess
how each variable was associated with whether respondents had
knowledge of their last injection partner's HCV status. Models 1 and 3
from the Smith et al. study are not replicated here due to our substan-
tially smaller sample size.
Our model mirrored the Smith et al. model, but with four distin-
guishable differences. First, race/ethnicity was included in the Smith et
al. model, but this information was impractical for our rural Puerto
Rican sample as all but a very small number of participants in the
study identified as Puerto Rican. Second, Smith et al. measured home-
lessness by whether participants had ever been homeless. Our partici-
pants were asked only about homelessness during the 12 months
prior to the interview. Third, due to differences in average income be-
tween Puerto Rico and the U.S. mainland, an annual income of $5000
was used as the threshold point between high-income and low-income,
as opposed to the $15,000 marker used by Smith and colleagues. A
threshold of $5000 was chosen to allow income percentiles to remain
roughly proportional. U.S. Census data shows that the median 2012 in-
come for the U.S. was $51,915 (U.S. Census Bureau, 2015a) and $19,518
for Puerto Rico (U.S. Census Bureau, 2015b). Keeping the same ratio,
$15,000 on the mainland is comparable to $5638 on the island. Because
our data on income was collected at the ordinal level, using a tipping
point of $5000 is the best available option.
Finally, as our samplewas substantially smaller, only one participant
in the final sample was over the age of 65, this individual was binned
down into the next younger age category and the highest age category
was not used. Though data was collected from 315 participants, skip
patterns in the questionnaire resulted in only 162 respondents on our
dependent variable – if they had knowledge of their last injection
partner's HCV status. Respondents who reported either a) never
injecting with a partner, or b) injecting with multiple partners or in a
shooting gallery on last injection were skipped on this question. List
wise deletion for missing data across independent and control variables
resulted in a loss of 8 additional cases, giving us a final sample-size of
154. t-Tests revealed significant differences between our analytic sam-
ple and our excluded sample in four areas: respondents in the analytic
sample were more likely to be HCV positive (p = 0.0446), less likely
to make $5000 a year or more (p = 0.0184), less likely to be unem-
ployed (p = 0.0175) vs. employed, and more likely to have some
other employment status (0.0269) than be employed, such as being a
student or retired.
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3. Results
Of the 154 individuals in the analytical sample, 55.8% reported
HCV+ status, 24% reported HCV− status, and 20.1% were unsure of
their HCV status. The vast majority of our sample was men, with
women making up only 11.7%. Ages were grouped in categories for
analysis, but the mean age was 42.21 years. The majority of our sample
was unemployed (80.5%) and almost none made over $5000 a year
(3.9%). Just over half the rural Puerto Rico sample had graduated high
school. Around a third of our sample had been homeless in the past
year. Age at first injection was distributed relatively evenly, with just
under a 10% difference between themost and least common categories.
Details of the sample can be found in Table 1 below.
When following the analysis of Model 2 using the rural Puerto Rico
data, the main independent variable in Smith et al.'s analysis, HCV sta-
tus, was found to not be a significant correlate of having knowledge of
last injection partner's HCV status. Odds ratios were substantial – 1.46
for a positive status and 1.75 for a negative status (as comparted to an
unknown status) – and trended in the same direction as in the national
data. However, HCV status failed to reach significant p–values, or even
approach them, as a factor. Furthermore, Table 2 shows that confidence
intervals for these odds ratios are incredibly wide –with the upper limit
being a full order of magnitude larger than the lower limit for positive
status. Only one characteristic in the model was significantly associated
with knowledge of last injection partner's HCV status: gender. Women
were 5.295 times as likely to have knowledge of their last injection
partner's HCV status as men, and this was significant with a p-value
less than 0.01. In Smith et al., women were only 1.8 times as likely to
have knowledge of their last injection partner's HCV status. All other
factors that were statistically significant in the Smith et al. article, in-
cluding known HCV status, income, education, homelessness, and em-
ployment status, were not significant in our data, and failed to even
approach significance.
Due to our relatively small sample size, we ran an additional
model using robust standard errors. We find almost no difference be-
tween the robust model and our initial model. The robust model is
detailed in Table 3. Additionally, using a large number of controls vi-
olated common practice regarding logistic regression. Though some
research suggests these rules can be relaxed (Vittinghoff and
McCulloch, 2007), we ran an additional model using fewer controls.
This models also failed to find a significant relationship for our
main independent variables. Details of this simplified model can be
found in Table 4.
Table 1
Frequency distribution of variables.
Variable N Percentage
Self-reported HCV status
Positive 86 55.8
Negative 37 24.0
Unknown 31 20.1
Female 18 11.7
Age (years)
18–34 40 26.0
35–44 45 29.2
45–54 52 33.8
55+ 17 11.0
High school graduate or above 83 53.9
Homeless in past 12 months 55 35.7
Employment status
Employed 12 7.8
Disabled 9 5.8
Other (student, retired, etc) 9 5.8
Unemployed 124 80.5
High income ($5000+/year) 39 3.9
Age at first injection
Under 18 57 37.0
18–24 55 35.7
25+ 42 27.3
Serochecked on last injection partner 47 30.5
Table 2
Adjusted odds ratios of awareness of last injection partner's HCV status.
N = 154
Participant characteristics Adjusted odds ratio 95% confidence interval
Self-reported HCV status
Positive 1.4940 (0.5069, 4.4032)
Negative 1.7536 (0.5469, 5.6222)
Unknown Reference
Gender
Female 5.2954 (1.7221, 16.2831)
Male Reference
Age
55+ 1.6138 (0.3637, 7.1602)
45–55 1.5541 (0.5519, 4.3758)
35–45 1.1202 (0.3828, 3.2779)
18–34 Reference
Education
High school grad 1.2209 (0.5829, 2.557)
Less than HS Reference
Homeless in past 12 months
Yes 0.6551 (0.2766, 1.5514)
No Reference
Employment status
Unemployed 1.4911 (0.3477, 6.3935)
Disabled 1.4688 (0.1773, 12.1646)
Other 1.4626 (0.1615, 13.2433)
Employed Reference
Income
$5000/yr+ 1.5263 (0.6182, 3.7681)
Less than $15,000 Reference
Age at 1st injection
25+ 0.6204 (0.2257, 1.7048)
18–24 1.1987 (0.5001, 2.8735)
Under 18 Reference
Table 3
Adjusted odds ratios of awareness of last injection partner's HCV status, with robust stan-
dard errors.
N = 154
Participant characteristics Adjusted odds ratio 95% confidence interval
Self-reported HCV status
Negative 1.7536 (0.5469, 5.6222)
Positive 1.4940 (0.5069, 4.4032)
Unknown Reference
Gender
Female 5.2954 (1.7221, 16.2831)
Male Reference
Age
55+ 1.6139 (0.3637, 7.1602)
45–55 1.5541 (0.5519, 4.3758)
35–45 1.1202 (0.3828, 3.2779)
18–34 Reference
Education
High school grad 1.2209 (0.5829, 2.5573)
Less than HS Reference
Homeless in past 12 months
Yes 0.6551 (0.2766, 1.5514)
No Reference
Employment status
Unemployed 1.4911 (0.3477, 6.3935)
Disabled 1.4688 (0.1773, 12.1646)
Other 1.4626 (0.1615, 13.2433)
Employed Reference
Income
$5000/yr+ 1.5263 (0.6182, 3.7681)
Less than $15,000 Reference
Age at 1st injection
25+ 0.6204 (0.2257, 1.7048)
18–24 1.1987 (0.5001, 2.88735
Under 18 Reference
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4. Discussion
Our sample was similar to the larger, urban sample used by Smith
and colleagues in many ways, but also unique in many ways as well.
The twowere comparable on age at first injection, age overall, education
level (thought the rural sample was slightly less educated), and had
similar distributions of HCV status. Our rural sample had fewer
women, fewer homeless, and fewer low-income respondents.
The findings from our data are vastly different from those found in
prior work on HCV serosorting. While Smith et al. found that self-re-
ported HCV status (either positive or negative), income, education,
homelessness, and employment status were all associated with having
knowledge last injection partner's HCV status in the general U.S. popu-
lation, none of these served as correlates in our sample of rural Puerto
Ricans. Our results did mirror the finding from the general population
that age is not strongly associatedwith attempted serosorting, however,
in that it was unrelated to having knowledge of last injection partner's
HCV status.
Whereas research on the U.S. mainland revealed that around 40% of
PWID attempted to serosort on HCV (Burt et al., 2009) and Smith et al.'s
study using similar questions found that 37.7% of PWID who shared
equipment had knowledge of their last injection partner's HCV status,
this was only true for 30.5% of respondents in rural Puerto Rico. Despite
being the biggest factor in Smith et al.'s study of PWID across the U.S.
mainland, knowing your own HCV status had no influence on
attempting to serosort for PWID in rural Puerto Rico, via asking your
last partner about their HCV status.
It is possible that our inability to obtain similar results is due to our
drastically smaller sample size. However, we did run additional tests
to examine this possibility, and still failed to obtain a significant rela-
tionship between HCV status and knowledge of last injection partner's
HCV status.
It should also be noted that our findings contrast those of Smith and
colleagues' urban sample, in that we find a stronger effect for HCV− re-
spondents than for those who are HCV+. This was the opposite in the
urban study, which found that HCV+ respondents were 4.1 times and
HCV− respondents were 2.5 times as likely as their peers with an un-
known HCV status to have knowledge of their last injection partner's
HCV status. We find that HCV+ respondents are 1.49 times as likely
and HCV− respondents are 1.75 times as likely as their peers with an
unknown HCV status to have knowledge of their last injection partner's
HCV status.
In other words, PWID with HCV are more likely to know their last
partner's HCV status than their peers without HCV in the urban sample.
In our rural sample, we find the opposite: that PWID without HCV are
more likely than their peers with the virus to know their last partner's
HCV status. This suggests that the burden of preventing transmission
may be on those without HCV in rural Puerto Rico. This may be unique
to this community, as previous research suggests that PWID perceive
the burden of preventing new infections to be on those already infected
with HCV (Treloar et al., 2015).
Only one factor from Smith et al.'s study persisted: gender. Gender
was found to be a much bigger factor in our PR data than in the general
population: female PWID from rural Puerto Ricowere over five times as
likely to have knowledge of their last injection partner's HCV status as
male PWID, compared to nearly twice as likely in the U.S. population
as a whole. In our sample, women were less likely to self-report being
HCV+ than men, and a comparatively smaller percentage of women
who completed anHCV testwith us had positive results aswell. Howev-
er, simple t-tests found that these differences were not significant. Fur-
thermore, previous work found that women who inject drugs are
actually 2–3 times more likely to acquire HCV than men (Lidman et
al., 2009; Maher et al., 2007), suggesting that the benefits of attempting
to serosort by knowing your injection partner's HCV status may be
smaller than originally thought. However, women also share equipment
more often than men (Frajzyngier et al., 2007) and are more likely to
borrow needles (Evans et al., 2003) as well. It is possible that this is
the cause for both their increased likelihood of infection, as well as
their increased vigilance in serosorting behaviors. Not only do they
have more opportunities for infection, but having more opportunities
may alsomake the risk of infectionmore salient, leading to greater like-
lihood of asking their last partner about their HCV status.
Thefinding that Puerto Rican PWID behave in uniqueways is not en-
tirely a new one. Previous research found that Puerto Rican PWID are
more likely to share needles and other equipment than their mainland
counterparts, and Puerto Rican natives who immigrate to the U.S. main-
land often make changes to their risk behaviors (Deren et al., 2003).
These results point to another aspect of risk behavior in which rural
Puerto Rican PWID represent unique challenges to programs aimed at
lowering HCV infection and risk of infection, and likely HIV infection
as well (Dombrowski et al., 2013a,b; Khan et al., 2013; Friedman et al.,
1997).
Finally, our results supported the finding from Smith et al. that age at
first injection is not a significant factor for knowing your last injection
partner's HCV status. It is interesting, however, that both studies
found that PWID who did not begin injecting until they were 25 years
of age or older were less likely to have knowledge of their last injection
partner's HCV status than their peers who began injecting earlier in life.
Though neither study found this to be a significant factor at the 95% con-
fidence level, it did approach significance in the Smith et al. study. The
possibility exists that people who begin drug use later in life, when
they are presumably wiser and more mature, are actually less likely to
have this knowledge andmay take part in riskier behavior. To the extent
that this finding seems to defy conventional wisdom, future research
could benefit from exploring this relationship further.
5. Limitations
Themost important limitation in this study is the drastically smaller
sample size in comparison to Smith et al.'s study. It should be noted that
a substantial portion of our obtained samplewas not included in our an-
alytical sample, because they had injected with multiple partners on
their last injection. This may skew our results and impact generalizabil-
ity, as the riskiest respondents were not included in our analysis here.
Furthermore, our rural sample does differ from the larger urban sample
on some key demographics, such as gender and homelessness. Differ-
ences between the two samplesmay be due to these demographic char-
acteristics, rather than something unique about the culture surrounding
injection drug use in rural Puerto Rico.
Whereas Smith and colleagues had a sample size of 4506 in their re-
search, ours is limited to 154. However, Smith et al.'s main independent
variable – HCV status – had p-values of less than 0.001 and large effect
sizes, whereas HCV status in our data had smaller effect sizes and p-
values ranging from 0.345 to 0.467. To put it another way, compared
to unknown HCV status, HCV+ participants were 1.49 (CI: 0.51, 4.40)
times as likely to have knowledge of their last injection partner's HCV
status, with HCV− participants being 1.75 (CI: 0.55, 5.62) times as like-
ly. Comparatively, Smith et al. found HCV+ participants to be 4.1 (CI:
3.4, 4.9) times as likely to have knowledge of their last injection
partner's HCV status, with HCV− participants being 2.5 (CI: 2.0, 3.0)
Table 4
Adjusted odds ratios of serochecking, robust standard errors, simplified model.
N = 154
Participant characteristics Adjusted odds ratio 95% confidence interval
Self-reported HCV status
Negative 2.0792 (0.6815, 6.3437)
Positive 1.6257 (0.5999, 4.4053)
Unknown Reference
Gender
Female 4.3938 (1.5546, 12.4183)
Male Reference
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times as likely, compared to those with an unknown HCV status. Given
this, it is unlikely that the variation in findings are due only to sample
sizes.
Furthermore, though both studies find that PWID who know their
own HCV status are more likely to know their last partner's status, the
trend is flipped for confirmed negatives and confirmed positives in
our study. In other words, the strongest relationship in the large urban
study by Smith and colleagues was for HCV+ respondents, whereas it
was strongest for HCV− respondents in our rural sample. If knowing
your own HCV status is indeed a significant factor in knowing your
last injection partners HCV status in rural Puerto Rico, it is likely that
this relationship is muchweaker than on the U.S. mainland. Additional-
ly, it is comparatively stronger for HCV− PWID than HCV+ PWID, the
reverse of what we see on the mainland. Using sample sizes that are
more comparable is suggested for future research.
6. Conclusion
This study provides evidence that PWID in rural Puerto Rico behave
differently and may have different norms regarding HCV serosorting
than PWID in urban communities on the U.S. mainland. Despite being
the biggest factor on the mainland, knowing your own HCV status ap-
pears to have no recognizable influence on knowing the HCV status of
your last injection partner in rural Puerto Rico. This is a substantial con-
trast between the two communities, and one that should be considered
when designing preventative interventions and treatments.
While this may point to a situation of critical need (such as for edu-
cation on the benefits of serosorting), future outreach programs can po-
tentially see this lack of protective and preventative behaviors as an
opening for immediate intervention. By a combined approach of both
testing and education aimed at the long-term health risk of living with
HCV, health professionals can potentially reduce the risk associated
with ignoring status discordance altogether—to put it bluntly, there is
nowhere to go but up. The extent to which the collective behaviors
discussed here are limited to rural Puerto Rico, or rural areas more gen-
erally, remains is unknown. However, it seems likely that the combina-
tion of HCV saturation in PWID communities and the low levels of status
reporting found in some other contexts (Miller et al., 2003) suggest that
our results may carry over to other regions as well.
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